Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5061804 | 0.80 | BRD4 (0.33) | BRD4 | |
| SCHEMBL17888966 | 0.80 | — | — | |
| SCHEMBL9118111 | 0.80 | APEX1 (0.31) | — | |
| SCHEMBL5260795 | 0.76 | BRD4 (0.36) | BRD4 | |
| SCHEMBL1408376 | 0.74 | MAPT (0.35) | — | |
| SCHEMBL29810264 | 0.73 | GSK3A (0.38) | — | |
| SCHEMBL5881899 | 0.72 | APEX1 (0.33) | — | |
| SCHEMBL1518987 | 0.72 | ADAM17 (0.32) | — | |
| SCHEMBL6206197 | 0.72 | TSHR (0.48) | BRD4 | |
| SCHEMBL9674486 | 0.71 | PTGS1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119326916-A | Multiple active targeting tumor nano-drug with multimode image function and immune activation effect and preparation method thereof | 北京科技大学 | 2025-01-21 | — | — | CN | claimed |
| CN-119326916-A | Multiple active targeting tumor nano-drug with multimode image function and immune activation effect and preparation method thereof | 北京科技大学 | 2025-01-21 | — | — | CN | disclosed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | disclosed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-1999047168-A2 | INDUCTION AND ENHANCEMENT OF THE IMMUNE RESPONSE TO TYPE-2 T CELL-INDEPENDENT ANTIGENS CONJUGATED TO LIPID OR LIPID-CONTAINING MOIETIES | HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5650270-A | DETECTABLE SIGNALS FOR LABELS AND ANALYZING | NORTHEASTERN UNIVERSITY (US) | 1997-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | BRD4 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.